LANSING, Mich., Feb. 4, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (KBLB) (the "Company" or "Kraig") announced today that it is accelerating its pilot production program, as a result of positive initial data from the first stage of the trial.
The acceleration to the second phase of the program is designed to increase production capacity of Monster Silk™, the Company's recombinant spider silk, by more than tenfold over the first stage. Kraig's strategy calls on further accelerating the production program by initiating a third stage, if the program continues to meet its targets.
The first phase of the pilot production program for Monster Silk™ is continuing, even as phase two is being launched. The purpose of the program is to verify scalability and favorable production economics of Monster Silk™, to significantly increase production, and to form the basis of large scale commercial production of the Company's recombinant spider silks.
"The initial success of the first stage has given us the confidence to accelerate the program," said Kraig founder and CEO, Kim Thompson. "We are now well ahead of the schedule that we envisioned even a few weeks ago. This is a critical step forward in the commercializing of our laboratory discoveries. The launching of stage two, which I view as the heart of the pilot production program, is the most exciting and momentous event in the Company's history, second only to our invention of Monster Silk™."
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 firstname.lastname@example.orgSource:Kraig Biocraft Laboratories, Inc